DexCom, Inc. - Common Stock (NQ:DXCM)

86.90 +1.54 (+1.80%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

50 51 Next >

Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today ↗

April 30, 2024

Via Benzinga

Dexcom Stock Continues To Post Very Healthy Profits, Returns ↗

April 30, 2024

Dexcom earns a lofty No. 5 rank among its peers in the 130-stock Medical-Products industry group. It got a rating upgrade Tuesday.

Via Investor's Business Daily

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

April 26, 2024

Via Benzinga

Peering Into DexCom's Recent Short Interest ↗

April 25, 2024

Via Benzinga

Dexcom Beats First-Quarter Views And Raises Sales Outlook, But Shares Crumble ↗

April 25, 2024

The company raised the lower bound of its sales guidance for the year.

Via Investor's Business Daily

Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review ↗

April 26, 2024

Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.

Via Investor's Business Daily

Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket ↗

April 26, 2024

Via Benzinga

$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today ↗

April 17, 2024

Via Benzinga

Why NASDAQ:DXCM Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

April 11, 2024

Via Chartmill

The Analyst Verdict: DexCom In The Eyes Of 4 Experts ↗

April 10, 2024

Via Benzinga

Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

April 26, 2024

Via Benzinga

DexCom (DXCM) Q1 2024 Earnings Call Transcript ↗

April 26, 2024

DXCM earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

DXCM Stock Earnings: DexCom Beats EPS, Beats Revenue for Q1 2024 ↗

April 25, 2024

DXCM stock results show that DexCom beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 25, 2024

Via Benzinga

Dexcom Reports First Quarter 2024 Financial Results

April 25, 2024

From DexCom, Inc.

Via Business Wire

Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating ↗

April 25, 2024

On Thursday, implantable lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

Via Investor's Business Daily

3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback ↗

April 20, 2024

Today’s episode of Full Court Finance at Zacks dives into the recent stock market pullback. We then turn our attention to three innovators in their respective industries—Vertiv, Align Technology, and...

Via Talk Markets

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher ↗

April 18, 2024

ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use.

Via Investor's Business Daily

3 Weight-Loss ETFs to Profit From the Obesity Drug Boom ↗

April 17, 2024

Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.

Via InvestorPlace

Topics ETFs

Disruptive Forces: 3 Game-changing Stocks Reshaping the Tech Landscape ↗

April 13, 2024

This April, discover three game-changing tech stocks with disruptive technologies poised to future-proof your portfolio in 2024.

Via InvestorPlace

Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit ↗

April 12, 2024

Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end?

Via Investor's Business Daily

Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In ↗

April 10, 2024

DoorDash, DexCom, and Advanced Micro Devices are three Nasdaq stocks to sell before reality sets in as exuberance may be fading.

Via InvestorPlace

3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild ↗

April 10, 2024

Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments

Via InvestorPlace

DexCom Stock Sees IBD Stock Market Rating Sweetens Ups; Earns 83 RS Rating ↗

April 08, 2024

The Relative Strength (RS) Rating for DexCom stock entered a new percentile Monday, with a rise from 80 to 83.

Via Investor's Business Daily

2 Growth Stocks to Buy Hand Over Fist in April ↗

April 08, 2024

These healthcare companies' target markets substantially overlap.

Via The Motley Fool

7 Nasdaq Stocks to Sell in April Before They Crash & Burn ↗

April 03, 2024

The momentum in growth companies is likely to run out. Move on from these Nasdaq stocks to sell in April before it's too late.

Via InvestorPlace

Dexcom Publishes Annual Sustainability Report

April 03, 2024

From DexCom, Inc.

Via Business Wire

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

April 02, 2024

From DexCom, Inc.

Via Business Wire

DexCom Stock Gains from GLP-1 Diabetic Users

April 02, 2024

DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People

Via MarketBeat

3 Overvalued S&P 500 Stocks for Your ‘Do NOT Buy’ List ↗

April 01, 2024

The S&P 500’s current P/E ratio is 30% higher than a year ago, making it easier to find overvalued S&P 500 stocks to buy.

Via InvestorPlace

Topics Stocks

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

50 51 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.